Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer - author's reply

被引：1
|
作者：
Hong, Hyeyeon [1 ]
Choi, Jonggi [1 ]
机构：
[1] Univ Ulsan, Liver Ctr, Asan Med Ctr, Dept Gastroenterol,Coll Med, Seoul, South Korea
来源：
CLINICAL AND MOLECULAR HEPATOLOGY | 2024年 / 30卷 / 02期
基金：
新加坡国家研究基金会;
关键词：
Antiviral agent; Tenofovir; Lipid; DOUBLE-BLIND; PHASE-3;
D O I：
10.3350/cmh.2024.0123
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] COST CONSEQUENCE ANALYSIS OF TENOFOVIR ALAFENAMIDE VS TENOFOVIR DISOPROXIL FUMARATE FOR THE MANAGEMENT OF CHRONIC HEPATITIS B: AN INDIAN SCENARIO
    Hadigal, Sanjay
    Naidu, Ravishankar
    HEPATOLOGY, 2020, 72 : 480A - 481A
  • [42] Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection
    Wai-Kay Seto
    Man-Fung Yuen
    James Fung
    Ching-Lung Lai
    Hepatology International, 2013, 7 : 327 - 334
  • [43] Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection
    Seto, Wai-Kay
    Yuen, Man-Fung
    Fung, James
    Lai, Ching-Lung
    HEPATOLOGY INTERNATIONAL, 2013, 7 (02) : 327 - 334
  • [44] Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection
    Jones, J.
    Colquitt, J.
    Shepherd, J.
    Harris, P.
    Cooper, K.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 23 - 29
  • [45] Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B Virus Infection in the African American Community
    Mor, Yechiel
    Wang, Jing
    Rizwan, Aliza
    Badia, Victoria
    Naylor, Paul
    Ehrinpreis, Murray
    Mutchnick, Milton G.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S537 - S538
  • [46] Tenofovir Alafenamide Fumarate, Tenofovir Disoproxil Fumarate and Entecavir: Which is the Most Effective Drug for Chronic Hepatitis B? A Systematic Review and Meta-analysis
    Ma, Xuefeng
    Liu, Shousheng
    Wang, Mengke
    Wang, Yifen
    Du, Shuixian
    Xin, Yongning
    Xuan, Shiying
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2021, 9 (03) : 335 - 344
  • [47] Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate
    Kaneko, Shun
    Kurosaki, Masayuki
    Tamaki, Nobuharu
    Itakura, Jun
    Hayashi, Tsuguru
    Kirino, Sakura
    Osawa, Leona
    Watakabe, Keiya
    Okada, Mao
    Wang, Wan
    Shimizu, Takao
    Higuchi, Mayu
    Takaura, Kenta
    Yasui, Yutaka
    Tsuchiya, Kaoru
    Nakanishi, Hiroyuki
    Takahashi, Yuka
    Watanabe, Mamoru
    Izumi, Namiki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (11) : 2004 - 2010
  • [48] Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study
    Su, Pei-Yuan
    Su, Wei-Wen
    Hsu, Yu-Chun
    Huang, Siou-Ping
    Yen, Hsu-Heng
    PEERJ, 2021, 9
  • [49] Cost-effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece
    Sinakos, Emmanouil
    Kachru, Nandita
    Tsoulas, Christos
    Jeyakumar, Sushanth
    Smith, Nathaniel J.
    Yehoshua, Alon
    Cholongitas, Evangelos
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2024, 13 (04) : e230090
  • [50] Predictors of HBeAg loss in HBeAg-positive patients with chronic hepatitis B during treatment with tenofovir alafenamide or tenofovir disoproxil fumarate
    Pan, Calvin Q.
    Li, Michael Kin Kong
    Lee, Kwan Sik
    Balabanska, Rozalina I.
    Flaherty, John F.
    Kim, Kyungpil
    Myers, Robert P.
    Subramanian, Mani
    Abdurakhmanov, Djamal
    Ma, Mang M.
    Bae, Ho
    Agarwal, Kosh
    HEPATOLOGY, 2016, 64 : 931A - 931A
12345